Akebia Therapeutics, Inc.

AKBA US00972D1054

🆔
Registration No.
4308099
💰
Capitalization
Small-cap

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

🔗
Website
https://www.akebia.com
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
26
🙍
Insiders
7
Person Price Shares Total Published Completed
Ostrowski Erik
CBO 		3.67
USD 		41,314
Sold 		151,622
USD 		30/06/2025 30/06/2025
Malabre Richard C
CCO 		4.01
USD 		15,000
Sold 		60,150
USD 		09/06/2025 09/06/2025
Malabre Richard C
CCO 		4.01
USD 		15,000
Sold 		60,150
USD 		09/06/2025 09/06/2025
Malabre Richard C
CCO 		3.53
USD 		13,334
Sold 		47,069
USD 		04/06/2025 04/06/2025
Malabre Richard C
CCO 		3.53
USD 		13,334
Sold 		47,069
USD 		04/06/2025 04/06/2025
Butler John P.
CEO 		1.83
USD 		46,409
Sold 		84,928
USD 		03/03/2025 03/03/2025
Burke Steven Keith
CMO 		1.83
USD 		7,144
Sold 		13,074
USD 		03/03/2025 03/03/2025
Burke Steven Keith
CMO 		2.10
USD 		27,236
Sold 		57,196
USD 		31/01/2025 03/02/2025
Grund Nicholas
CCO 		2.10
USD 		55,621
Sold 		116,804
USD 		31/01/2025 03/02/2025
Butler John P.
CEO 		2.10
USD 		97,982
Sold 		205,762
USD 		31/01/2025 03/02/2025

Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include Akebia Therapeutics, Inc. to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Last 52W Low 52W High All-Time Low All-Time High β
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Butler John P. 6 596,889.75 99,481.63 01/02/2024 03/03/2025
Malabre Richard C 5 277,862.24 55,572.45 03/02/2025 09/06/2025
Burke Steven Keith 7 215,073.46 30,724.78 25/08/2023 03/03/2025
Ostrowski Erik 1 151,622.38 151,622.38 30/06/2025 30/06/2025
Grund Nicholas 1 116,804.10 116,804.10 03/02/2025 03/02/2025
Dahan Michel 3 73,913.66 24,637.89 27/02/2024 13/05/2024
Hadas Nicole R. 3 35,843.80 11,947.93 27/02/2024 13/05/2024

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.